松龄血脉康胶囊治疗高脂血症肝阳上亢证对照研究

A RANDOMIZED CONTROLLED, DOUBLE BLIND, DOUBLE DUMMY STUDY ON SONGLING XUE- MAIKANG CAPSULE AGAINST HYPERLIPIDEMIA (LIVER YANG ASCENDING)

目的:探讨松龄血脉康胶囊治疗高脂血症(肝阳上亢证)的临床疗效。方法:选择符合标准的高脂血症病人100例,随机分为治疗组(松龄血脉康胶囊+绞股兰总苷胶囊安慰剂)和对照组(绞股兰总苷胶囊+松龄血脉康胶囊安慰剂)各50例,治疗4周。于治疗前3周、治疗后6周后进行总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)、极低密度脂蛋白(VLDL-C)、总胆固醇—高密度脂蛋白/高密度脂蛋白(TC—HDL-C/HDL-C)血脂含量测定。结果:治疗组血脂总疗效为80.0％,与对照组比较无明显差异(P>0.05);TC、TG、HDL-C、LDL-C、VLDL-C及TC—HDL-C/HDL-C较治疗前显著降低(P<0.05),但与对照组比较无显著性差异(P>0.05)。结论:松龄血脉康胶囊是一种安全、疗效可靠、适合长期服用的降血脂药物。

Objective:To valuate the clinical effect of Songling Xuemaikang capsule on hyperlipidemia. Methods: 100 cases with hyperlipidemia coinciding with the diagnostic standard were assigned randomly into two groups: trial group (Jiaogulan zhongdai capsule placebo plus Songling Xuemaikang capsule, n = 50) and control group (Jiaogulan Zhongdai capsule plus Songling Xuemaikang capsule placebo.n = 50). They were treated for 4 weeks. Total cholesterol (TO ,triglyceride(TG) .high density lipoprotein (HDL-C),low density lipoprotein (LDL-C). very low density lipoprotein (VLDL-C) .total cholesterol-high density lipoprotein/high density lipoprotein (TC-HDL-C/HDL-C)were determined at 3 weeks before treatment and 6 weeks after treatment. Results: Total effect rate for blood lipid in trial group was 80% and TC,TG,HDL-C,VLDL-C,TC-HCL-C/HDL-C was lower than those before treatment significantly,but there were no significant differences between the two groups (P>0. 05)-Conclusion:Songling Xuemaikang capsule is a kind of safe,reliable antilipimic agent can be applied for a long-term treatment. It is worthy applying widespread further.